The fact that there was a response (reducing or clearing leukemic blasts) to decitabine by the 21/21 AML patients with p53 mutations and that response was not durable in every case means that there is a mechanism to overcome the defective p53 pathway in cells that contain mutant p53 proteins. The gene discussed is TP53; the disease is acute myeloid leukemia.